Defence Therapeutics Inc.
DTC
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 94.11% | -94.67% | -67.96% | -52.51% | -68.67% |
| Depreciation & Amortization | -26.35% | 149.02% | 36.84% | 5,816.67% | 8,250.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.61% | -92.77% | -77.47% | -32.97% | -21.20% |
| Operating Income | 25.61% | 92.77% | 77.47% | 32.97% | 21.20% |
| Income Before Tax | 32.65% | 90.60% | 72.84% | 27.82% | 0.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.65% | 90.60% | 72.84% | 23.44% | 0.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.65% | 90.60% | 72.84% | 23.44% | 0.83% |
| EBIT | 25.61% | 92.77% | 77.47% | 32.97% | 21.20% |
| EBITDA | 25.05% | 92.91% | 77.85% | 35.34% | 23.58% |
| EPS Basic | 38.91% | 91.06% | 73.73% | 27.18% | 13.67% |
| Normalized Basic EPS | 28.99% | 91.00% | 73.82% | 31.47% | 13.75% |
| EPS Diluted | 38.91% | 91.06% | 73.73% | 27.18% | 13.67% |
| Normalized Diluted EPS | 28.99% | 91.00% | 73.82% | 31.47% | 13.75% |
| Average Basic Shares Outstanding | 10.32% | 4.76% | 3.77% | 5.29% | 14.93% |
| Average Diluted Shares Outstanding | 10.32% | 4.76% | 3.77% | 5.29% | 14.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |